Cantor Fitzgerald Downgrades Tobira Therapeutics (TBRA) to Hold Following Takeover
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Cantor Fitzgerald downgraded Tobira Therapeutics (NASDAQ: TBRA) from Buy to Hold with a price target of $42.00 (from $19.00) after the company agreed to be acquired by Allergan.
Shares of Tobira Therapeutics closed at $38.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tobira Therapeutics (TBRA) PT Raised to $45 at Leerink
- Citi Downgrades VF Corp. (VFC) to Neutral
- Nomura Securities Downgrades Wipro Ltd. (WIT) to Reduce
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesCantor Fitzgerald
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!